Navigation Links
Masimo to Report Third Quarter 2007 Financial Results on October 30, 2007
Date:10/18/2007

Conference call and webcast with Masimo CEO and CFO to begin after markets

close at 2:00 pm PT (5:00 pm ET)

IRVINE, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Masimo Corporation (Nasdaq: MASI), the inventor of Pulse CO-Oximetry and Read-Through Motion and Low Perfusion pulse oximetry, today announced it will release third quarter financial results for the period ended September 29, 2007 after the market closes on Tuesday, October 30, 2007.

A conference call to review the results will begin at 2:00 p.m. PT (5:00 p.m. ET) and will be hosted by Joe E. Kiani, Chairman and Chief Executive Officer, and Mark P. de Raad, Executive Vice President & Chief Financial Officer.

A live web cast of the conference call will be available online from the investor relations page of the Company's corporate web site at http://www.masimo.com. The dial-in numbers are (800) 659-2037 for domestic callers and (617) 614-2713 for international callers. The reservation number for both dial-in numbers is 20647778. After the live web cast, the call will remain available on Masimo's web site through November 30, 2007. In addition, a telephonic replay of the call will be available until November 13, 2007. The replay dial-in numbers are (888) 286-8010 for domestic callers and (617) 801-6888 for international callers. Please use reservation code 39086455.

About Masimo

Masimo (Nasdaq: MASI) develops innovative monitoring technologies that significantly improve patient care-helping solve "unsolvable" problems. In 1995, the company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET, and with it virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies have confirmed that Masimo SET technology allows clinicians to accurately monitor blood oxygen saturation in critical care situations. Our Masimo SET platform has significantly addressed many of the previous technology limitations, has substantially contributed to improved patient outcomes and has been referred to by several industry sources as the gold standard in pulse oximetry. In 2005, Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at http://www.masimo.com.

Investor Contact:

Mark P. de Raad

Executive Vice President and

Chief Financial Officer

(949) 297-7080

mderaad@masimo.com

Media Contact:

Tom McCall

Vice President, Corporate Communications

Masimo Corporation

949-297-7075

tmccall@masimo.com

Masimo, SET, Signal Extraction Technology, Radical, Radical-7, Rad57, APOD, and Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications are registered trademarks of Masimo Corp. ARM, Acoustic Respiratory Monitoring, BiFi, Rainbow, Patient SafetyNet, SpCO, SpMet, SpHb, PVI and Pulse CO-Oximeter are trademarks of Masimo Corp.


'/>"/>
SOURCE Masimo Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Assess the In Vivo Activation of Signal Transduction Pathways with PathDetect Reporting Systems
2. New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence Humanized Renilla GFP Reporter
3. Signal Transduction Reporting Systems Using Cis-Acting Enhancer Elements
4. Stable HeLa Luciferase Reporter Cell Lines Expressing GAL4 Fusion Transactivators
5. Versatile Reporter Vectors for Monitoring Viral Transduction
6. In Vivo Signal Transduction Pathway Reporting Systems
7. Improved Vectors for PathDetect Trans-Reporting Systems
8. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
9. Cis-Reporting System Monitors Intracellular Calcium Mobilization
10. Cis-Reporting System Monitors Intracellular Calcium Mobilization
11. PatchMan - Test Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)...  Neogen Corporation (NASDAQ: NEOG ) announced ... Incorporated (NASDAQ: SNES ) related to the ... SenesTech. The two firms had worked together since 2014 ... was approved by the U.S. Environmental Protection Agency. ... could only be used by a Licensed Pesticide Applicator. Further, ...
(Date:1/24/2017)... and DURHAM, N.C. , ... IRB in customer service and technology, announces that ... the organization as Biosafety Officer. In ... leadership to develop and manage a forthcoming institutional biosafety ... for research organizations navigating the IBC landscape. The new ...
(Date:1/24/2017)... 2017  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... medicine, today announced positive efficacy results from the ... showed additional motor function improvement at 6-months and ... in AIS-A patients with complete cervical spinal cord ... motor function is critically important to patients with ...
(Date:1/24/2017)... ... January 24, 2017 , ... Men who have a high ... a positive association with increased prostate growth or benign prostatic hyperplasia, according to ... involved 571 Korean men who underwent urological examinations, including serum prostate specific ...
Breaking Biology Technology:
(Date:1/12/2017)... Jan. 12, 2017  New research undertaken by Fit ... the future.  1,000 participants were simply asked which office technology ... we may consider standard issue.  Insights on what will ... also gathered from futurists and industry leaders including Penelope ... Canton .  Some of these findings ...
(Date:1/11/2017)... , Jan. 11, 2017 Intoxalock, a leading ... the release of its patent-pending calibration device. With this ... perform calibrations, securely upload data logs and process repairs ... customer. "Fighting drunk driving through the application ... public at large, but also for the customer who ...
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
Breaking Biology News(10 mins):